LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives

Major advances in understanding how genetics underlies Parkinson’s disease (PD) have provided new opportunities for understanding disease pathogenesis and potential new targets for therapeutic intervention. One such target is leucine-rich repeat kinase 2 (LRRK2), an enigmatic enzyme implicated in bo...

Descripción completa

Detalles Bibliográficos
Autores principales: Atashrazm, Farzaneh, Dzamko, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5076802/
https://www.ncbi.nlm.nih.gov/pubmed/27799832
http://dx.doi.org/10.2147/CPAA.S102191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5076802/
https://www.ncbi.nlm.nih.gov/pubmed/27799832
http://dx.doi.org/10.2147/CPAA.S102191

Ejemplares similares